DA Berry Publications

A Selection of Recent Publications

Donald A. Berry, Ph.D.
Department of Biostatistics
The University of Texas
M. D. Anderson Cancer Center

2002

Berry DA. The utility of mammography for women 40 to 50 years of age (con). In: Devita VT, Hellman S, Rosenberg SA, editors. Progress in Oncology. Sudbury, MA: Jones and Bartlett; 2002. p. 233-259.
Berry DA. Clinical trial design. In: Bast R, et al., editors. Helene Harris Memorial Trust Conference Proceedings. (To appear, 2002)
Berry DA. Adaptive clinical trials and Bayesian statistics (with discussion). Accepted for publication in Pharmaceutical Report, by the American Statistical Association, 2002.
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Stadtmauer E, Costanza M, Freytes CO, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of the Cancer and Leukemia Group B trials with data from the Autologous Bone Marrow Transplant Registry. Journal of Clinical Oncology 2002; 20(3):743-750.
Berry DA, Iversen E, Gudbjartsson DF, Hiller E, Garber J, Peshkin B, Lerman C, Watson P, Lynch H, Hilsenbeck S, Rubinstein W, Hughes K, Parmigiani G. Validation of BRCAPRO, sensitivity testing of BRCA1 and BRCA2, and implications for the prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology 2002; 20(11):2701-2712.
Berry DA, Seltzer JD, Xie C, Wright DL, Smith JSC. Assessing probability of ancestry using simple sequence repeat profiles: applications to maize hybrides and inbreds. Genetics 2002; 161:813-824.
Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, BUdman DR, Henderson IC, Norton L, Hayes DF. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative study from protocols 8541/8869. Journal of Clinical Oncology 2002; 20(3):732-742.
Pecora A, Lazarus H, Stadtmauer E, Winter J, Van Vilet A, Berry D, Gray R, Jennis A, Goldberg S, Cooper B, Preti R. Role of induction with high dose chemotherapy in autologous stem cell transplant for metastatic breast cancer. Accepted for publication in Bone Marrow Transplantation, 2002.
Petros WP, Broadwater G, Berry DA, Jones RB, Vredenburgh JJ, Gilbert CJ, Gibbs JP, Colvin MO, Peters WP. Association of high-dose cyclophosphamide, cisplatin and carmustine pharmacokinetics with response, toxicity and dosing weight in patients with primary breast cancer. Accepted for publication in Clinical Cancer Research, 2002.
Skinner CS, Schildkraut J, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer E, Iglehart JD, Futreal PA, Rimer BK. Tailored versus non-tailored materials to facilitate BRCA testing decisions. Accepted for publication in Genetic Testing, 2002.

2001

Berry DA. Editorial: Role of population-based studies in assessing genetic cancer risk. Journal of the National Cancer Institute 2001; 93(16):1188-1189.
Berry DA. Sequential statistical methods. In: Smelser NJ, Baltes PB, editors. International Encyclopedia of the Social and Behavioral Sciences. Amsterdam: Elsevier Science; 2001.
Berry DA, Mueller P, Grieve AP, Smith M, Parke T, Blazek R, Mitchard N, Krams M. Adaptive Bayesian designs for dose-ranging drug trials. In: Gatsonis C, Carlin B, Carriquiry A, editors. Case Studies in Bayesian Statistics, Volume V. New York: Springer-Verlag; 2001. p.99-181.
Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, Everett T, Harpole D, Moore MB, Berry DA, Rizzeri D, Vredenburgh JJ, Bentley RC. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. Journal of Clinical Oncology 2001; 19(6):1698-1706.
Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clinical Cancer Research 2001; 7(9):2703-2711.
Lewis RJ, Berry DA, Cryer H, Fost N, Krome R, Washington GR, Houghton J, Blue JW, Bechhofer R, Cook T, Fisher M. Monitoring a clinical trial conducted under the Food and Drug Administration regulations allowing a waiver of prospective informed consent:the diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. Annals of Emergency Medicine 2001; 38(4):397-404.
Zhang W, Labordé PM, Coombes KR, Berry DA, Hamilton SR. Cancer genomics: promises and complexities. Clinical Cancer Research 2001; 7(8):2159-2167.

2000

Berry DA. Review of Pharmaceutical Experimental Design by Garth A. Lewis, Didier Mathieu, Roger Phan-Tan Luu. Journal of the American Statistical Association 2000; 95:339.
Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of Clinical Oncology 2000; 18(20):3471-3479.
Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, Hayes DF. Association of angiogenesis in lymph node metastases with outcome of breast cancer. Journal of the National Cancer Institute 2000;92(6):486-492.
Iversen ES Jr, Parmigiani G, Berry DA, Schildkraut JM. Genetic susceptibility and survival: Application to breast cancer. Journal of the American Statistical Association 2000;95:28-42.
Stangl DK, Berry DA. Meta-analysis: past and present challenges. In: Stangl DK, Berry DA, editors. Meta-Analysis in Medicine and Health Policy. New York: Marcel Dekker; 2000. p. 1-28.

1999

Abrams J, Aisner J, Cirrincione C, Berry DA, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. A dose-response trial of megestrol acetate in advanced breast cancer: CALBG 8741. Journal of Clinical Oncology 1999; 17:64-73.
Ashih H, Gustilo-Ashby T, Myers E, Andrews J, Clarke-Pearson DL, Berry DA, Berchuck A. Cost-effectiveness of treatment of early stage endometrial cancer. Gynecologic Oncology 1999; 74:208-216.
Berry DA, Hochberg Y. Bayesian perspectives on multiple comparisons. Journal of Statistical Planning and Inference 1999; 82:215-277.
Blackwell K, Broadwater G, Haroon Z, Berry DA, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with extent of disease involvement. Journal of Clinical Oncology 1999; 18:600-608.
Bluman LG, RImer BK, Berry DA, Borstelmann N, Regan K, Schildkraut J, Winter E. Attitudes, knowledge and risk perceptions of women with breast cancer considering testing for BRCA1 and BRCA2. Journal of Clinical Oncology 1999; 17:1040-1046.
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Wood WC, Frei E III, McIntyre OR, Schilsky RL. The safety and efficacy of using a single agent or phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study: CALGB 8642. Journal of Clinical Oncology 1999; 17(5):1397.
Iversen ES, Parmigiani G, Berry DA. Validating Bayesian prediction models: A case study in genetic susceptibility to breast cancer. In: Carlin B, Carriquiry A, Gatsonis C, Gelman A, Kass RE, Verdinelli I, West M, editors. Case Studies in Bayesian Statistics, Volume IV. New York: Springer-Verlag; 1999. p. 321-338.
Iversen ES, Parmigiani G, Berry DA, Schildkraut JM. Genetic Susceptibility and survival: application to breast cancer. Journal of the American Statistical Association 1999; 95:28-42.
Parmigiani G, Berry DA, Iversen E, Mueller P, Schildkraut J, Winer E. Modeling risk of breast cancer and decisions about genetic testing. In: Carlin B, Carriquiry A, Gatsonis C, Gelman A, Kass RE, Verdinelli I, West M, editors. Case Studies in Bayesian Statistics, Volume IV. New York: Springer-Verlag; 1999. p. 415-436.
Rizzieri DA, Vredenburgh JV, Jones R, Shpall EJ, Hussein A, Broadwater G, Berry DA, Petros Wp, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and predictive factors in metastatic breast cancer undergoing aggressive induction therapy followed by high dose chemotherapy with autologous stem-cell support. Journal of Clinical Oncology 1999; 17:2064-3074.
Tengs To, Berry DA. The cost-effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Disease Management and Clinical Outcomes, 1999; Winter:15-24.
Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for BRCA1 breast-ovarian cancer susceptibility gene: a decision analysis. Medical Decision Making 1999; 18:365-375.